Prophylaxis for Cancer-Associated Venous Thromboembolic Disease
VTE is common among patients with cancer and represents an appreciable risk, with associated morbidity and mortality. Accurate VTE risk assessment is important in identifying appropriate candidates for VTE prophylaxis and at times can prevent unnecessary use of anticoagulants. Selecting a suitable regimen in these patients requires guidance from physicians with experience treating various oncology subpopulations.
Category
  • Venous Thromboembolic Disease
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates in the Management of Hepatobiliary Cancers
Keeping clinicians up-to-date with the most recent NCCN Guidelines for Hepatobiliary Cancers recommendations and emerging therapies can help improve clinical decision-making and patient outcomes.
Category
  • Hepatobiliary Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
NCCN Guidelines® for Central Nervous System Cancers: Updates in the Treatment of Adult Patients with Glioma
With the use of genetic and molecular testing, gliomas can be differentiated more accurately in terms of prognosis and, in some instances, response to different therapies. The updated WHO classification of tumors of the central nervous system (CNS) takes into account the importance of molecular data for accurately diagnosing CNS tumors. Detection of genetic or epigenetic alterations could expand clinical trial options for a patient with a brain tumor.
Category
  • Central Nervous System Cancers
  • Glioma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Updates in the Treatment of Metastatic Colorectal Cancer
Targeted therapy approaches for mCRC continue to evolve as new data helps define how to best improve outcomes. Decisions regarding treatment for patients with mCRC require that clinicians be familiar with existing and new targeted therapies as well as the most effective and tolerable combination regimens.
Category
  • Colorectal Cancer
  • Rectal Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Plenary Session: Sleep Disorders, Fatigue, and Cognitive Function in Cancer Survivors
Sleep, fatigue and cognitive function are important in improving quality of life in cancer survivors. These issues are often not addressed appropriately and further education and awareness can promote increased quality of life in cancer survivors.
Category
  • Supportive Care Topics
  • Survivorship
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 ASWB continuing education credit
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: The Role of PD-L1 Therapy in the Early Treatment of Triple Negative Breast Cancer
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
What is Biomarker Testing, and Why Is It Important?
Practitioners need to keep abreast of developments in molecular testing in order to educate patients about their testing results and potentially identify patients that should be tested. The fundamental information about biomarker testing presented during this session should assist participants to better understand the content presented throughout the Biomarkers Congress.
Category
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Evaluating Immune Checkpoint Inhibition Response Biomarkers
Targeting the anti-tumor immune response has become a widely used strategy for the therapy of patients with advanced solid tumors, but not all patients respond, and immune-related side effects plus the high cost of these therapies increase the need for effective biomarkers to ensure that the immune checkpoint inhibitors are used in patients with the best chance of success. Clinicians need to be aware of the assays that are most appropriate to use based on the tumor type and the pitfalls of each testing technology.
Category
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Clinical Scenario #1: Applying Biomarkers in Risk Stratification of Localized Prostate Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Clinical Scenario #2: Applying Biomarkers in Breast Cancer
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation

Pages